World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
39586
World Ranking
7358
National Ranking
3853

David Schiff publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David Schiff sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 481 publications — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David Schiff D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David Schiff sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David Schiff is affiliated with the University of Virginia in the United States. Their research focuses primarily on the field of Medicine, with notable contributions in subfields such as Genetics, Radiology, Nuclear Medicine and Imaging, Neurology, Pulmonary and Respiratory Medicine, and Oncology.

Their main research topics include:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Neuroblastoma Research and Treatments
  • Meningioma and schwannoma management
  • Cancer Genomics and Diagnostics
  • Neurofibromatosis and Schwannoma Cases

David Schiff has published extensively, with research appearing frequently in the following venues:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • Journal of Neuro-Oncology
  • Neuro-Oncology Advances
  • Neuro-Oncology Practice

Among the recent papers authored in collaboration with others, notable publications include:

  • "Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions," 2020, Neuro-Oncology
  • "Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline," 2021, Journal of Clinical Oncology
  • "Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions," 2022, Neuro-Oncology
  • "Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma," 2023, Journal of Clinical Oncology
  • "SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors," 2021, Neuro-Oncology

Frequent coauthors in their work have included:

  • Patrick Y. Wen
  • Andrew B. Lassman
  • David A. Reardon
  • Evanthia Galanis
  • Martin J. van den Bent

Best Publications

  • A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

    Mark R. Gilbert;James J. Dignam;Terri S. Armstrong;Terri S. Armstrong;Jeffrey Scott Wefel

  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

    Henry S. Friedman;Michael D. Prados;Patrick Y. Wen;Tom Mikkelsen

  • Law as a Social System

    Niklas Luhmann;Klaus A. Ziegert;Fatima Kastner;Richard Nobles

  • NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

    Roger Stupp;Eric T. Wong;Andrew A. Kanner;David Steinberg

  • Response assessment criteria for brain metastases: proposal from the RANO group

    Nancy U Lin;Eudocia Q Lee;Hidefumi Aoyama;Igor J Barani

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Patrick Y. Wen;Michael Weller;Eudocia Quant Lee;Brian M. Alexander

  • microRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes

    Yunqing Li;Fadila Guessous;Ying Zhang;Charles DiPierro

  • Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review

    Leland Rogers;Igor Barani;Marc Chamberlain;Thomas J. Kaley

  • Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

    M. J. van den Bent;J. S. Wefel;D. Schiff;M. J. B. Taphoorn

  • Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

    David A. Reardon;Karen L. Fink;Tom Mikkelsen;Timothy F. Cloughesy

  • Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome

    Patrick G. Morris;Denise D. Correa;Joachim Yahalom;Jeffrey J. Raizer

  • Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma

    Gaurav D. Shah;Joachim Yahalom;Denise D. Correa;Rose K. Lai

  • Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

    Patrick Y. Wen;W. K Alfred Yung;Kathleen R. Lamborn;Patricia L. Dahia

  • Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

    Susan M. Chang;Patrick Wen;Timothy Cloughesy;Harry Greenberg

  • Malignant spinal-cord compression

    Dheerendra Prasad;David Schiff

  • The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.

    Janet E. Olson;Carol A. Janney;Ravi D. Rao;James R. Cerhan

  • microRNA-34a is tumor suppressive in brain tumors and glioma stem cells

    Fadila Guessous;Ying Zhang;Alexander Kofman;Alessia Catania

  • Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.

    Sigal Grisariu;Batia Avni;Tracy T. Batchelor;Martin J. van den Bent

  • Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American brain tumor consortium study

    Michael D. Prados;W. K.A. Yung;Kurt A. Jaeckle;H. Ian Robins

  • Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

    Paul D. Brown;Sunil Krishnan;Jann N. Sarkaria;Wenting Wu

Frequent Co-Authors

Patrick Y. Wen
Patrick Y. Wen Harvard University
David A. Reardon
David A. Reardon Harvard University
Tracy T. Batchelor
Tracy T. Batchelor Brigham and Women's Hospital
Timothy F. Cloughesy
Timothy F. Cloughesy University of California, Los Angeles
Keith L. Ligon
Keith L. Ligon Harvard University
Lauren E. Abrey
Lauren E. Abrey University of Zurich
Susan M. Chang
Susan M. Chang University of California, San Francisco
Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
Michael A. Vogelbaum
Michael A. Vogelbaum Cleveland Clinic
Lisa M. DeAngelis
Lisa M. DeAngelis Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Medicine but seeking alternative or complementary career paths, there are many online degree options in health and healthcare administration. An online healthcare administration degree provides essential management skills and health system knowledge, offering a pathway to administrative roles in hospitals and clinics.

Those looking for advanced leadership opportunities can consider the cheapest online mha programs to earn a Master’s in Healthcare Administration (MHA) at an affordable cost. This degree can fast-track your career in health services management and hospital administration.

For practicing nurses, the best online dnp programs allow for the highest level of clinical training and leadership within nursing, further expanding professional opportunities and expertise.

If pharmacy is your focus, exploring an online pharmd program can prepare you to become a licensed pharmacist while offering the flexibility of remote study.

These online degrees provide accessible routes into high-demand healthcare fields, each with strong career growth potential and the flexibility suited for working adults and career changers.

Best Scientists Citing David Schiff

Trending Scientists